Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

231
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
231
Inflammatory Response01:28

Inflammatory Response

9.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
9.5K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

657
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
657

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Chemoprevention of Colon Carcinogenesis by Oleanolic Acid and Its Analog in Male F344 Rats and Modulation of COX-2 and Apoptosis in Human Colon HT-29 Cancer Cells.

Pharmaceutical research·2026
Same author

Genome-Wide CRISPR Analysis Uncovers Metformin and NSAID Combination as a Chemopreventive Approach in Smoking-Associated Oral Cancer.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Galactokinase 1 Inhibition-Induced Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells Is Associated with AKT Signaling Downregulation.

International journal of molecular sciences·2026
Same author

Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD.

bioRxiv : the preprint server for biology·2025
Same author

Chromatin Remodulator CHD4: A Potential Target for Cancer Interception.

Genes·2025
Same author

Correction: Singh et al. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models. <i>Cells</i> 2024, <i>13</i>, 1463.

Cells·2025

Related Experiment Video

Updated: Sep 28, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

584

Anti-Inflammatory Drugs Decrease the PD-L1 Expression and Increase the CD8+ T-Cell Infiltration.

Chinthalapally V Rao1

  • 1Department of Medicine, Hematology/Oncology Section, Stephenson Cancer Center, Center for Cancer Prevention and Drug Development, University of Oklahoma Health Sciences Center, VA Medical Center, Oklahoma City, Oklahoma.

Cancer Prevention Research (Philadelphia, Pa.)
|April 4, 2022
PubMed
Summary
This summary is machine-generated.

Nonsteroidal anti-inflammatory drugs (NSAIDs) like celecoxib and naproxen reduce programmed death-ligand 1 (PD-L1) expression and boost tumor-infiltrating lymphocytes in colon tumors. These findings suggest NSAIDs could be valuable for preventing PD-L1-positive colon polyps.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

453

Related Experiment Videos

Last Updated: Sep 28, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

584
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

453

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are investigated for their potential role in cancer chemoprevention.
  • Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein implicated in tumor immune evasion.
  • The cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway is frequently dysregulated in cancer.

Discussion:

  • NSAIDs, specifically celecoxib and naproxen, were shown to decrease PD-L1 expression in colonic tumors.
  • These NSAIDs also increased the infiltration of Type I tumor-infiltrating lymphocytes, including CD8+ T cells.
  • The observed effects were linked to the inhibition of the COX-2/PGE2 pathway in preclinical models.

Key Insights:

  • NSAIDs modulate intratumoral immunity by suppressing immune checkpoint blockade.
  • Reduced PD-L1 expression and increased CD8+ T cell influx are key mechanisms.
  • The COX-2/PGE2 pathway is a critical target for NSAID-mediated immune regulation in colon cancer.

Outlook:

  • NSAIDs show promise as chemopreventive agents for PD-L1-positive colonic polyps.
  • Further research could explore combination therapies involving NSAIDs and immunotherapies.
  • Clinical trials may validate the chemopreventive potential of NSAIDs in high-risk populations.